Evista (raloxifene), the new "designer estrogen"
You're going to hear a lot about Evista (raloxifene), the new "designer estrogen" from Lilly.
It's INITIALLY approved to prevent osteoporosis.
But Evista and future designer estrogens will revolutionize hormone replacement therapy because they're more selective. They mimic the effects of estrogen in SOME tissues...but not others.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote